Kjetil Taskén

Kjetil Taskén

Auto-generated profile, based on publicly available information

Kjetil Taskén

Oslo University Hospital

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2004 in Physiological Reviews
Verified
Journal Article
Closed access
PDF file
KTKjetil Taskén
Kjetil Taskén
EAEinar Martin Aandahl
Einar Martin Aandahl
Taskén, Kjetil, and Einar Martin Aandahl. Localized Effects of cAMP Mediated by Distinct Routes of Protein Kinase A. Physiol Rev 84: 137–167, 2004; 10.1152/physrev.00021.2003.—More than 20% of the human genome encodes proteins involved in transmembrane and intracellular signaling pathways. The cAMP-protein kinase A (PKA) pathway is one of the most common and versatile signal pathways in eukaryotic cells and is involved in regulation of cellular functions in almost all tissues in mammals. Various extracellular signals converge on this signal pathway through ligand binding to G protein-coupled receptors, and the cAMP-PKA pathway is therefore tightly regulated at several levels to maintain specificity in the multitude of signal inputs. Ligand-induced changes in cAMP concentration vary in duration, amplitude, and extension into the cell, and cAMP microdomains are shaped by adenylyl cyclases that form cAMP as well as phosphodiesterases that degrade cAMP. Different PKA isozymes with distinct biochemical properties and cell-specific expression contribute to cell and organ specificity. A kinase anchoring proteins (AKAPs) target PKA to specific substrates and distinct subcellular compartments providing spatial and temporal specificity for mediation of biological effects channeled through the cAMP-PKA pathway. AKAPs also serve as scaffolding proteins that assemble PKA together with signal terminators such as phosphatases and cAMP-specific phosphodiesterases as well as components of other signaling pathways into multiprotein signaling complexes that serve as crossroads for different paths of cell signaling. Targeting of PKA and integration of a wide repertoire of proteins involved in signal transduction into complex signal networks further increase the specificity required for the precise regulation of numerous cellular and physiological processes.

1 September 2001 in Cell
Verified
Journal Article
Closed access
ACAnna Cederberg
Anna Cederberg
LGLine M. Grønning
Line M. Grønning
BABo Ahrén
Bo Ahrén
KTKjetil Taskén
Kjetil Taskén
PCPeter Carlsson
Peter Carlsson
SESven Enerbäck
Sven Enerbäck

1 December 2018 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
CSCharlotte Schwab
Charlotte Schwab
AGAnnemarie Gabrysch
Annemarie Gabrysch
POPeter Olbrich
Peter Olbrich
VPVirginia Patiño
Virginia Patiño
KWKlaus Warnatz
Klaus Warnatz
BGBodo Grimbacher
Bodo Grimbacher

19 February 2001 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
TVTorkel Vang
Torkel Vang
KTKnut Martin Torgersen
Knut Martin Torgersen
VSVibeke Sundvold
Vibeke Sundvold
MSManju Saxena
Manju Saxena
FLFinn Olav Levy
Finn Olav Levy
KTKjetil Taskén
Kjetil Taskén
In T cells, cAMP-dependent protein kinase (PKA) type I colocalizes with the T cell receptor–CD3 complex (TCR/CD3) and inhibits T cell function via a previously unknown proximal target. Here we examine the mechanism for this PKA-mediated immunomodulation. cAMP treatment of Jurkat and normal T cells reduces Lck-mediated tyrosine phosphorylation of the TCR/CD3 ζ chain after T cell activation, and decreases Lck activity. Phosphorylation of residue Y505 in Lck by COOH-terminal Src kinase (Csk), which negatively regulates Lck, is essential for the inhibitory effect of cAMP on ζ chain phosphorylation. PKA phosphorylates Csk at S364 in vitro and in vivo leading to a two- to fourfold increase in Csk activity that is necessary for cAMP-mediated inhibition of TCR-induced interleukin 2 secretion. Both PKA type I and Csk are targeted to lipid rafts where proximal T cell activation occurs, and phosphorylation of raft-associated Lck by Csk is increased in cells treated with forskolin. We propose a mechanism whereby PKA through activation of Csk intersects signaling by Src kinases and inhibits T cell activation.

1 November 2006 in Molecular Cell
Verified
Journal Article
Closed access
MGMatthew G. Gold
Matthew G. Gold
BLBirgitte Lygren
Birgitte Lygren
PDPawel Dokurno
Pawel Dokurno
NHNaoto Hoshi
Naoto Hoshi
GMGeorge McConnachie
George McConnachie
DBDavid Barford
David Barford

1 May 2016 in Cell Reports
Verified
Journal Article
Open access
LLLisa L. Liu
Lisa L. Liu
JLJohannes Landskron
Johannes Landskron
EAEivind H. Ask
Eivind H. Ask
MEMonika Enqvist
Monika Enqvist
ESEbba Sohlberg
Ebba Sohlberg
Vivien BéziatVivien Béziat
Vivien Béziat
Infection by human cytomegalovirus (HCMV) leads to NKG2C-driven expansion of adaptive natural killer (NK) cells, contributing to host defense. However, approximately 4% of all humans carry a homozygous deletion of the gene that encodes NKG2C (NKG2C(-/-)). Assessment of NK cell repertoires in 60 NKG2C(-/-) donors revealed a broad range of NK cell populations displaying characteristic footprints of adaptive NK cells, including a terminally differentiated phenotype, functional reprogramming, and epigenetic remodeling of the interferon (IFN)-γ promoter. We found that both NKG2C(-) and NKG2C(+) adaptive NK cells expressed high levels of CD2, which synergistically enhanced ERK and S6RP phosphorylation following CD16 ligation. Notably, CD2 co-stimulation was critical for the ability of adaptive NK cells to respond to antibody-coated target cells. These results reveal an unexpected redundancy in the human NK cell response to HCMV and suggest that CD2 provides "signal 2" in antibody-driven adaptive NK cell responses.